Deals in Depth: August 2011
Executive Summary
Merck is tasking Zymeworks' Azymetric platform for bi-specific cancer and autoimmune antibodies in a $187 million alliance. Par paid $410 million for generics company Anchen, while Baxter acquired additional medical delivery systems through its $380 million purchase of Baxa. With $334 million raised, device financing surpassed biopharma's $224 million in fundraising in August, thanks to large late-stage rounds from NeuroPace, Restoration Robotics and Entellus.
You may also be interested in...
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Health And Wellness Trademark Review 12 January, 2021
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Need a specific report? 1000+ reports available
Buy Reports